Aceso Life Science Group 過去の業績

過去基準チェック /06

Aceso Life Science Groupの収益は年間平均-6.9%の割合で減少していますが、 Consumer Finance業界の収益は年間増加しています。収益は年間2% 15.8%割合で増加しています。

主要情報

-6.9%

収益成長率

0.9%

EPS成長率

Consumer Finance 業界の成長	-2.1%
収益成長率	15.8%
株主資本利益率	-44.6%
ネット・マージン	-4,200.0%
前回の決算情報	31 Mar 2024

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

収支内訳

Aceso Life Science Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:474 収益、費用、利益 ( )HKD Millions
日付	収益	収益	G+A経費
31 Mar 24	11	-462	124
31 Dec 23	105	-441	124
30 Sep 23	198	-420	123
30 Jun 23	203	-342	125
31 Mar 23	207	-264	126
31 Dec 22	161	-301	134
30 Sep 22	115	-338	141
30 Jun 22	143	-354	147
31 Mar 22	170	-370	153
31 Dec 21	8	-197	162
30 Sep 21	-154	-25	171
30 Jun 21	-141	-200	188
31 Mar 21	-129	-376	204
31 Dec 20	-43	-523	209
30 Sep 20	43	-671	213
30 Jun 20	9	-477	201
31 Mar 20	-25	-284	189
31 Dec 19	48	-162	196
30 Sep 19	120	-40	203
30 Jun 19	148	-211	211
31 Mar 19	175	-381	219
31 Dec 18	200	-533	223
30 Sep 18	224	-686	226
30 Jun 18	237	-565	226
31 Mar 18	250	-445	227
31 Dec 17	235	-1,209	205
30 Sep 17	220	-1,972	183
30 Jun 17	169	-2,526	158
31 Mar 17	118	-3,079	133
31 Dec 16	95	-1,911	119
30 Sep 16	71	-743	106
30 Jun 16	57	-109	97
31 Mar 16	42	524	89
31 Dec 15	20	498	80
30 Sep 15	-1	471	70
30 Jun 15	-3	997	73
31 Mar 15	-5	1,523	75
31 Dec 14	6	1,281	79
30 Sep 14	17	1,039	82
30 Jun 14	22	466	80
31 Mar 14	26	-107	78
31 Dec 13	-13	-122	67

質の高い収益: 474は現在利益が出ていません。

利益率の向上: 474は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 474は利益が出ておらず、過去 5 年間で損失は年間6.9%の割合で増加しています。

成長の加速: 474の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 474は利益が出ていないため、過去 1 年間の収益成長をConsumer Finance業界 ( -2.1% ) と比較することは困難です。

株主資本利益率

高いROE: 474は現在利益が出ていないため、自己資本利益率 ( -44.62% ) はマイナスです。

Aceso Life Science Group 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Recent updates

New minor risk - Share price stability

Insufficient new directors

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06